![]() |
CiteULike | ![]() |
djmonstermo's CiteULike | ![]() |
![]() |
|
![]() |
Register | ![]() |
Log in | ![]() |
An Autoinflammatory Disease with Deficiency of the Interleukin-1-Receptor Antagonist.by: Ivona Aksentijevich, Seth L L. Masters, Polly J J. Ferguson, Paul Dancey, Joost Frenkel, Annet van Royen-Kerkhoff, Ron Laxer, Ulf Tedgård, Edward W W. Cowen, Tuyet-Hang H. Pham, Matthew Booty, Jacob D D. Estes, Netanya G G. Sandler, Nicole Plass, Deborah L L. Stone, Maria L L. Turner, Suvimol Hill, John A A. Butman, Rayfel Schneider, Paul Babyn, Hatem I I. El-Shanti, Elena Pope, Karyl Barron, Xinyu Bing, Arian Laurence, Chyi-Chia R C. Lee, Dawn Chapelle, Gillian I I. Clarke, Kamal Ohson, Marc Nicholson, Massimo Gadina, Barbara Yang, Benjamin D D. Korman, Peter K K. Gregersen, P Martin M. van Hagen, A Elisabeth E. Hak, Marjan Huizing, Proton Rahman, Daniel C C. Douek, Elaine F F. Remmers, Daniel L L. Kastner, Raphaela Goldbach-Mansky
|
Reviews
[Write a review of this article]
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
Posting History
AbstractBACKGROUND: Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone. METHODS: We studied nine children from six families who had neonatal onset of sterile multifocal osteomyelitis, periostitis, and pustulosis. Response to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first patient prompted us to test for the presence of mutations and changes in proteins and their function in interleukin-1-pathway genes including IL1RN. RESULTS: We identified homozygous mutations of IL1RN in nine affected children, from one family from Newfoundland, Canada, three families from the Netherlands, and one consanguineous family from Lebanon. A nonconsanguineous patient from Puerto Rico was homozygous for a genomic deletion that includes IL1RN and five other interleukin-1-family members. At least three of the mutations are founder mutations; heterozygous carriers were asymptomatic, with no cytokine abnormalities in vitro. The IL1RN mutations resulted in a truncated protein that is not secreted, thereby rendering cells hyperresponsive to interleukin-1beta stimulation. Patients treated with anakinra responded rapidly. CONCLUSIONS: We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote this autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN. The absence of interleukin-1-receptor antagonist allows unopposed action of interleukin-1, resulting in life-threatening systemic inflammation with skin and bone involvement. (ClinicalTrials.gov number, NCT00059748.) Copyright 2009 Massachusetts Medical Society.
BibTeX record
RIS record